iRadimed price target raised to $72 from $60 at Roth MKM
Roth MKM raised the firm’s price target on iRadimed (IRMD) to $72 from $60 and keeps a Buy rating on the shares. The company reported solid Q4 ...
Hosted on MSN1mon
Inseego rises after Roth MKM upgrades to Buy on balance sheet recap, core product growth
New products and expanded carrier relationships are expected to further drive continued Mobile Solutions (hotspot) growth in 2025 and 2026 (8% and 20%+ in our model)," Roth MKM added.
Roth MKM says Valens Semiconductor synergies with Acroname already materializing
Roth MKM analyst Suji Desilva noted that the firm is “encouraged” by Valens’ product platform targeting edge AI and conferencing platforms in ...